收藏切换
Introduction on the addendum to testing for carcinogenicity for pharmaceuticals
收藏切换
PDF
Yu ZHOU, Fang-hua HUANG, Qing-li WANG, Tao SUN
Chinese Journal of Clinical Pharmacology | 2025, 41(4) : 596 - 600
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(4): 596-600
Drug Evaluation and Administration
Introduction on the addendum to testing for carcinogenicity for pharmaceuticals
Full
Yu ZHOU, Fang-hua HUANG, Qing-li WANG, Tao SUN
Affiliations
  • Center for Drug Evaluation, China National Medical Products Administration, Beijing 100022, China
Published: 2025-02-28 doi: 10.13699/j.cnki.1001-6821.2025.04.030
Outline
收藏切换

Testing for carcinogenicity is a key toxicological test that supports marketing authorization and an important part of nonclinical safety studies for pharmaceuticals. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) S1B “Testing for carcinogenicity of pharmaceuticals” provides recommendations on approaches for evaluating the carcinogenic potential of pharmaceuticals which can include the conduct of a 2-year rat carcinogenicity study. With the application of the ICH S1B (R1) “Addendum to testing for carcinogenicity for pharmaceuticals” in China, sponsors are allowed to use the weight of evidence (WoE) method rather than the conventional 2-year rat carcinogenicity study, a more scientific and comprehensive assessment of the carcinogenic potential of certain molecules specified in ICH S1A “Guideline on the need for carcinogenicity studies of pharmaceuticals”. This addendum identifies key factors supporting WoE assessment and emphasizes the importance of survey investigative studies and emerging technology in assessing human carcinogenic risks. This article discusses the background information on the development of ICH S1B (R1), main technical issues, and follow-up work, in order to facilitate the understanding and implementation of this guideline.

testing for carcinogenicity  /  weight-of-evidence approach  /  carcinogenicity risk assessment  /  pharmaceutical
Yu ZHOU, Fang-hua HUANG, Qing-li WANG, Tao SUN. Introduction on the addendum to testing for carcinogenicity for pharmaceuticals[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (4) : 596 -600 . DOI: 10.13699/j.cnki.1001-6821.2025.04.030
Year 2025 volume 41 Issue 4
PDF
1
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.04.030
  • Receive Date:2024-08-15
  • Online Date:2026-08-04
  • Published:2025-02-28
Article Data
Affiliations
History
  • Received:2024-08-15
Affiliations
    Center for Drug Evaluation, China National Medical Products Administration, Beijing 100022, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.04.030
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT